BROOKS.NS
Brooks Laboratories Limited [BROOKS.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BROOKS.NS Stock Summary
Top 10 Correlated Stocks
BROOKS.NS
In the News
BROOKS.NS Financial details
Company Rating
Sell
Market Cap
2.77B
Income
-142.85M
Revenue
744.61M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
296
Optionable
No
Shortable
Yes
Earnings
27 May 2024
P/E
-28.99
Forward P/E
-
PEG
10.63
P/S
6.4
P/B
5.65
P/C
-
P/FCF
-
Quick Ratio
0.69
Current Ratio
1.25
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5.63
EPS next Y
-
EPS next Q
-
EPS this Y
8.27%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
2.6%
Revenue last 5Y
2.81%
Revenue Q/Q
-10.56%
EPS Q/Q
131.25%
-
-
-
-
SMA20
0.95%
SMA50
-25.87%
SMA100
-17.83%
Inst Own
-
Inst Trans
-
ROA
-15%
ROE
-40%
ROC
-0.16%
Gross Margin
29%
Oper. Margin
-19%
Profit Margin
-23%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
56.953606-185.7
52W High
-46.59%
52W Low
+76.43%
RSI
41
Rel Volume
0.05
Avg Volume
65.99K
Volume
3.15K
Perf Week
-11.75%
Perf Month
-19.58%
Perf Quarter
-7.58%
Perf Half Y
-14.72%
-
-
-
-
Beta
1.377
-
-
Volatility
3.68%, 7.81%
Prev Close
-1.2%
Price
98.8
Change
-3.14%
BROOKS.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 27.38 | 38.88 | 30.9 | 36.12 | 25.34 | |
| Net income per share | -7.37 | -13.71 | -7.77 | -7.74 | -8.38 | |
| Operating cash flow per share | -2.51 | -5.28 | 1.79 | -15.01 | -5.81 | |
| Free cash flow per share | -2.94 | -6.73 | -0.46 | -26.08 | -6 | |
| Cash per share | 1.65 | 0.86 | 0.86 | 0.96 | 0.55 | |
| Book value per share | 52.31 | 55.34 | 31.73 | 25.28 | 29.65 | |
| Tangible book value per share | 52.13 | 55.18 | 31.45 | 53.59 | 29.57 | |
| Share holders equity per share | 52.31 | 55.34 | 31.73 | 25.28 | 29.65 | |
| Interest debt per share | 16.98 | 17.42 | 13.82 | 11.26 | 3.49 | |
| Market cap | 988.86M | 271.19M | 1.53B | 1.82B | 1.56B | |
| Enterprise value | 1.28B | 543.6M | 1.83B | 2.05B | 1.62B | |
| P/E ratio | -6.68 | -1.11 | -7.89 | -9.42 | -7.44 | |
| Price to sales ratio | 1.8 | 0.39 | 1.98 | 2.02 | 2.46 | |
| POCF ratio | -19.58 | -2.89 | 34.29 | -4.86 | -10.73 | |
| PFCF ratio | -16.71 | -2.27 | -132.38 | -2.8 | -10.4 | |
| P/B Ratio | 0.94 | 0.28 | 1.93 | 2.88 | 2.1 | |
| PTB ratio | 0.94 | 0.28 | 1.93 | 2.88 | 2.1 | |
| EV to sales | 2.32 | 0.79 | 2.38 | 2.27 | 2.56 | |
| Enterprise value over EBITDA | -23.73 | -22.57 | 144.35 | -14.55 | -5.49 | |
| EV to operating cash flow | -25.26 | -5.79 | 41.14 | -5.46 | -11.18 | |
| EV to free cash flow | -21.56 | -4.54 | -158.78 | -3.14 | -10.83 | |
| Earnings yield | -0.15 | -0.9 | -0.13 | -0.11 | -0.13 | |
| Free cash flow yield | -0.06 | -0.44 | -0.01 | -0.36 | -0.1 | |
| Debt to equity | 0.3 | 0.28 | 0.4 | 0.4 | 0.09 | |
| Debt to assets | 0.19 | 0.18 | 0.19 | 0.13 | 0.06 | |
| Net debt to EBITDA | -5.34 | -11.31 | 24.01 | -1.61 | -0.22 | |
| Current ratio | 0.67 | 0.83 | 0.75 | 1.25 | 0.83 | |
| Interest coverage | -4.05 | -2.68 | -2.12 | -7.55 | -15.3 | |
| Income quality | 0.34 | 0.69 | -0.5 | 1.57 | 0.41 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.08 | 0.06 | 0.09 | 0.1 | 0.16 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.17 | 0.28 | -1.26 | 0.74 | 0.03 | |
| Capex to revenue | -0.02 | -0.04 | -0.07 | -0.31 | -0.01 | |
| Capex to depreciation | -0.13 | -0.39 | -0.79 | -3.76 | -0.07 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 93.11 | 130.65 | 74.47 | 66.36 | 74.76 | |
| ROIC | -0.09 | -0.13 | -0.13 | -0.19 | -0.33 | |
| Return on tangible assets | -0.09 | -0.15 | -0.12 | -0.1 | -0.19 | |
| Graham Net | -19.93 | -18.68 | -20.82 | -8.81 | -7.64 | |
| Working capital | -154.98M | -78.81M | -159.13M | 123.04M | -55.15M | |
| Tangible asset value | 1.05B | 981.36M | 784.6M | 1.34B | 737.54M | |
| Net current asset value | -308.38M | -215.3M | -351.28M | -4.09M | -81.38M | |
| Invested capital | 0.3 | 0.28 | 0.4 | 0.4 | 0.09 | |
| Average receivables | 181.66M | 214.7M | 232.44M | 270.1M | 220.14M | |
| Average payables | 268.17M | 266.03M | 285.1M | 294.77M | 256.85M | |
| Average inventory | 107.31M | 119.14M | 186.89M | 255.63M | 194.13M | |
| Days sales outstanding | 127.33 | 125.36 | 107.73 | 126.7 | 73.65 | |
| Days payables outstanding | 217.96 | 177.91 | 204.52 | 134.83 | 168.57 | |
| Days of inventory on hand | 80.74 | 94.02 | 155.96 | 132.53 | 81.53 | |
| Receivables turnover | 2.87 | 2.91 | 3.39 | 2.88 | 4.96 | |
| Payables turnover | 1.67 | 2.05 | 1.78 | 2.71 | 2.17 | |
| Inventory turnover | 4.52 | 3.88 | 2.34 | 2.75 | 4.48 | |
| ROE | -0.14 | -0.25 | -0.24 | -0.31 | -0.28 | |
| Capex per share | -0.43 | -1.45 | -2.25 | -11.07 | -0.19 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 6.13 | 5.09 | 6.3 | 9.51 | 8.29 | |
| Net income per share | -2.01 | -1.72 | -1.79 | -0.64 | -1.48 | |
| Operating cash flow per share | 1.87 | 0.35 | 0.35 | -3.59 | 0.33 | |
| Free cash flow per share | 1.87 | 0.35 | 0.35 | -3.62 | 0.33 | |
| Cash per share | 0.44 | 0.55 | 0.43 | 0.39 | 0 | |
| Book value per share | 55.64 | 29.65 | 29.65 | 30.93 | 0 | |
| Tangible book value per share | 0 | 29.57 | 0 | 30.88 | 0 | |
| Share holders equity per share | 55.64 | 29.65 | 29.65 | 30.93 | 0 | |
| Interest debt per share | 0.3 | 2.68 | 0.07 | 1.72 | 0.08 | |
| Market cap | 2.73B | 1.56B | 1.96B | 2.32B | 3.83B | |
| Enterprise value | 2.74B | 1.62B | 1.97B | 2.36B | 3.83B | |
| P/E ratio | -13.58 | -9.05 | -10.96 | -35.37 | -24.69 | |
| Price to sales ratio | 17.82 | 12.25 | 12.48 | 9.53 | 17.62 | |
| POCF ratio | 58.53 | 178.56 | 222.2 | -25.24 | 440.51 | |
| PFCF ratio | 58.53 | 178.56 | 222.2 | -25.01 | 440.51 | |
| P/B Ratio | 1.96 | 2.1 | 2.65 | 2.93 | 0 | |
| PTB ratio | 1.96 | 2.1 | 2.65 | 2.93 | 0 | |
| EV to sales | 17.89 | 12.76 | 12.55 | 9.69 | 17.62 | |
| Enterprise value over EBITDA | -32.36 | -44.04 | 8.04K | -233.51 | -119.52 | |
| EV to operating cash flow | 58.76 | 186.01 | 223.42 | -25.67 | 440.51 | |
| EV to free cash flow | 58.76 | 186.01 | 223.42 | -25.44 | 440.51 | |
| Earnings yield | -0.02 | -0.03 | -0.02 | -0.01 | -0.01 | |
| Free cash flow yield | 0.02 | 0.01 | 0 | -0.04 | 0 | |
| Debt to equity | 0 | 0.09 | 0 | 0.05 | 0 | |
| Debt to assets | 0 | 0.06 | 0 | 0.04 | 0 | |
| Net debt to EBITDA | -0.13 | -1.76 | 43.89 | -3.97 | 0 | |
| Current ratio | 0 | 0.83 | 0 | 1.25 | 0 | |
| Interest coverage | -14.43 | -2.35 | -2.43 | -7.77 | -17.1 | |
| Income quality | -0.93 | -0.2 | -0.2 | 5.61 | -0.22 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0.18 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.01 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | -0.09 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 50.19 | 33.9 | 34.57 | 21.1 | 0 | |
| ROIC | -0.07 | 0 | -0.05 | -0.02 | 0 | |
| Return on tangible assets | 0 | -0.04 | 0 | -0.02 | 0 | |
| Graham Net | 0.44 | -7.64 | 0.43 | -3.5 | 0 | |
| Working capital | 10.97M | -55.15M | 10.75M | 60.54M | 0 | |
| Tangible asset value | 0 | 737.54M | 0 | 789.81M | 0 | |
| Net current asset value | 10.97M | -81.38M | 10.75M | 35.42M | 0 | |
| Invested capital | 0 | 0.09 | 0 | 0.05 | 0 | |
| Average receivables | 79.5M | 63.77M | 63.77M | 78.73M | 78.73M | |
| Average payables | 186.63M | 116.85M | 116.85M | 83.68M | 83.68M | |
| Average inventory | 109.45M | 56.52M | 56.52M | 51.2M | 51.2M | |
| Days sales outstanding | 0 | 90.41 | 0 | 58.28 | 0 | |
| Days payables outstanding | 0 | 256.34 | 0 | 86.27 | 0 | |
| Days of inventory on hand | 0 | 123.98 | 0 | 52.78 | 0 | |
| Receivables turnover | 0 | 1 | 0 | 1.54 | 0 | |
| Payables turnover | 0 | 0.35 | 0 | 1.04 | 0 | |
| Inventory turnover | 0 | 0.73 | 0 | 1.71 | 0 | |
| ROE | -0.04 | -0.06 | -0.06 | -0.02 | 0 | |
| Capex per share | 0 | 0 | 0 | -0.03 | 0 |
BROOKS.NS Frequently Asked Questions
What is Brooks Laboratories Limited stock symbol ?
Brooks Laboratories Limited is a IN stock and trading under the symbol BROOKS.NS
What is Brooks Laboratories Limited stock quote today ?
Brooks Laboratories Limited stock price is $98.8 today.
Is Brooks Laboratories Limited stock public?
Yes, Brooks Laboratories Limited is a publicly traded company.
Something similar
Company Profile
- Volume Average 65.99K
- Market Capitalization 2.77B
- Employee 296
- CEO Mr. Prashant Rathi
- Headquarters Mumbai,IN
- IPO Date 2011-09-05
-
Website
https://www.brookslabs.net 
Brooks Laboratories Limited manufactures and sells pharmaceuticals on contract basis in India and internationally. It offers carbapenem drugs; tablets; dry syrup; liquid and dry power injections; and eye and ear drop. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.
